CALR and neoplasm: Already, a decade ago, Obeid and colleagues discovered calreticulin (CRT) exposure to be vital in dictating the immunogenicity of tumor cell death.[12] Accordingly, the recently reviewed paradigm of immunogenic cancer cell death (ICD) postulates that not only the event of cell death but also its inflammatory context is decisive for the immune system responding to dying tumor cells in a tolerogenic or immunogenic fashion.[13]